文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

外照射放疗联合镭-223治疗转移性激素敏感性前列腺癌患者的潜在放射敏感性生物标志物

A potential biomarker of radiosensitivity in metastatic hormone sensitive prostate cancer patients treated with combination external beam radiotherapy and radium-223.
PubMed 文献 · Radiother Oncol · 2023-12-20

ADRRAD试验评估外照射放疗联合镭-223治疗初诊骨转移性前列腺癌的安全性和可行性,本研究旨在寻找预测治疗反应的生物标志物。30例患者纳入分析,治疗期间所有患者DNA损伤均增加,晚期复发者病灶增加幅度大于早期复发者,且镭-223周期中DNA损伤增加与反应相关。结论提示监测循环淋巴细胞DNA损伤高于基线及红细胞和血红蛋白计数下降可能有助于预测治疗反应。

要点

  • 治疗期间所有患者DNA损伤均增加,晚期复发者病灶增加幅度大于早期复发者。
  • 镭-223周期中DNA损伤增加与这些患者的治疗反应相关。
  • 晚期生化复发者红细胞和血红蛋白计数下降幅度更大。

核心结论

  • 部分患者对联合治疗有反应,其他患者在治疗开始一年内复发。
  • 本研究识别出一种基于生物标志物的方法,可能有助于预测哪些患者对治疗有反应。

研究设计与样本

  • ADRRAD试验纳入30例新诊断骨转移性激素敏感性前列腺癌患者。
  • 在治疗前、镭-223第2至6周期前、治疗后8周和6个月采集血样,分离单核细胞并在所有时间点评估DNA损伤。

主要发现

  • 治疗期间所有患者DNA损伤均增加,晚期复发者病灶增加幅度大于早期复发者。
  • 镭-223周期中DNA损伤增加与这些患者的治疗反应相关。
  • 血液学计数分析显示,晚期生化复发者红细胞和血红蛋白计数下降幅度更大。
  • 部分患者对联合治疗有反应,其他患者在治疗开始一年内复发。

临床怎么用

  • 作者认为,通过监测循环淋巴细胞DNA损伤高于基线水平及治疗期间红细胞和血红蛋白计数下降,可能有助于预测哪些患者对治疗有反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The ADRRAD trial reported the safety and feasibility of the combination of external beam radiotherapy and radium-223 in the treatment of de novo bone metastatic prostate. This study aimed to determine if any biomarkers predictive of response to these treatments could be identified. EXPERIMENTAL DESIGN: 30 patients with newly diagnosed bone metastatic hormone sensitive prostate cancer were recruited to the ADRRAD trial. Blood samples were taken pre-treatment, before cycles 2 to 6 of radium-223, and 8 weeks and 6 months after treatment. Mononuclear cells were isolated and DNA damage was assessed at all timepoints. RESULTS: DNA damage was increased in all patients during treatment, with bigger increases in foci observed in patients who relapsed late compared to those who relapsed early. Increases in DNA damage during the radium-223 only cycles of treatment were specifically related to response in these patients. Analysis of hematology counts also showed bigger decreases in red blood cell and hemoglobin counts in patients who experienced later biochemical relapse. CONCLUSIONS: While some patients responded to this combination treatment, others relapsed within one year of treatment initiation. This study identifies a biomarker based approach that may be useful in predicting which patients will respond to treatment, by monitoring both increases in DNA damage above baseline levels in circulating lymphocytes and decreases in red blood cell and hemoglobin counts during treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Redmond KM, Turner PG, Cole A, et al. A potential biomarker of radiosensitivity in metastatic hormone sensitive prostate cancer patients treated with combination external beam radiotherapy and radium-223. Radiother Oncol. 2023. PMID: 38135185. doi:10.1016/j.radonc.2023.110063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。